Harte-Hanks, Inc. (HHS): Price and Financial Metrics
GET POWR RATINGS... FREE!
HHS Stock Summary
- With a one year PEG ratio of 7,757.96, Harte Hanks Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.68% of US stocks.
- HHS's price/sales ratio is 167.31; that's higher than the P/S ratio of 97.94% of US stocks.
- The volatility of Harte Hanks Inc's share price is greater than that of 99.98% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Harte Hanks Inc, a group of peers worth examining would be TRU, GHM, GOOS, BKI, and FSS.
- HHS's SEC filings can be seen here. And to visit Harte Hanks Inc's official web site, go to www.hartehanks.com.
HHS Stock Price Chart Interactive Chart >
HHS Price/Volume Stats
|Current price||$2.69||52-week high||$3.96|
|Prev. close||$2.75||52-week low||$1.10|
|Day high||$2.79||Avg. volume||21,692|
|50-day MA||$2.68||Dividend yield||N/A|
|200-day MA||$2.81||Market Cap||17.33M|
Harte-Hanks, Inc. (HHS) Company Bio
Harte-Hanks, Inc. provides various marketing services in the United States and internationally. The company was founded in 1970 and is based in San Antonio, Texas.
HHS Latest News Stream
|Loading, please wait...|
HHS Latest Social Stream
View Full HHS Social Stream
Latest HHS News From Around the Web
Below are the latest news stories about Harte Hanks Inc that investors may wish to consider to help them evaluate HHS as an investment opportunity.
Harte Hanks (HHS) to commence delisting procedure on NYSE in its failure to comply with the continued listing standardsThe company does not plan to appeal to NYSE for continue listing.The shares will begin trading on the OTCQX under the symbol HRTE. Source: Press Release...
Harte Hanks, Inc. Announces Suspension Of Trading And Commencement Of NYSE Delisting Procedures; Common Stock Expected To Begin Trading On The OTCQX
Harte Hanks, Inc. (NYSE: HHS) (the "Company" or "Harte Hanks"), a leading data-driven multi-channel marketing solutions firm, today announced the Company was notified by the New York Stock Exchange ("NYSE") on July 9, 2020, that the NYSE had determined to commence proceedings to delist the Company's common stock (the "Common Stock") as a result of the Company's failure to comply with the continued listing standard set forth in Section 802.02B of the NYSE Listed Company Manual to maintain either (i) at least $50 million in stockholders' equity or (ii) at least $50 million in total market capitalization on a 30-trading day average basis. The NYSE will announce a suspension date at such time as (i) the Company does not request a review of...
Harte-Hanks (HHS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Harte Hanks, Inc. (HHS), a leading behavioral marketing company, announced today that it has been selected by Flagship Biosciences to provide strategic marketing solutions in developing a new customer acquisition program. Flagship Biosciences is a leader in technology-driven tissue analysis, and provides expert tissue data insights to pharmaceutical, biotechnology and clinical diagnostic companies. Harte Hanks will be developing a targeted, multi-channel campaign including email, digital advertising and content creation to help Flagship Biosciences engage priority audiences, nurture leads and connect with potential clients.
Q4 2019 Harte Hanks Inc Earnings Call
HHS Price Returns